Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this is biotech. they are biotech management. biotechs move slowly and they're used to working slowly i'm sure.
a month feels like an eternity on the otc, but just to remind the board, it's only been a month since this takeover has been finalized and announced. in the meantime the company has done quite a bit to set the stage for what their plans are and have painted a picture of where the company stands and what that vision in.
today we see just another step in the process having been completed. without this filing, it's curtains as was previously pointed out. however, it's here and on time and it should tell the entire investment community that they're coming.
i haven't been worried about it, thus my initial take from the filing was that there wasn't anything of real note inside.
but it is significant and worth mentioning here since that point has garnered so much discussion.
from where i stand this is just a waiting game and a chance to slowly accumulate shares at a very low price. there's so much great DD here to confirm what oncolix is and where they plan to go.
on another note, news could be coming faster than some think with this big investors conference happening as i write this. remember that the the former CEO of Glaxo just put in more than a million dollars into this.
still way undervalued based on that alone. forget about any merger that's coming.
wouldn't shock me to see this touch a nickel this week.
It's official. No Reverse Split.
There's been no name change and there are no immediate plans for one.
This should officially eliminate that reverse split as a cause for concern since that was supposed to have been predicated on a name change that never happened. Remember, it was supposed to happen "immediately" following the closing.
Big filing today.
There's nothing particularly newsworthy within the filing itself that I see, but the fact they are filing and staying current is excellent news. Looks to me like they're right on track.
bids hidden. same story.
this is gonna blow when they're ready.
big week coming for oncolix/aepp
I've confirmed that this is indeed a legit company.
Huge things coming too!
gaps fill because these pump and dumps always crash. however this could gain 100000% before your precious gaps close.
what is questionable about the company?
smh
this is a biotech with a phase I drug.
there are not supposed to be any revenue at this point.
goodness folks, at least get your bashing arguments on point if you're gonna do it.
pgpm news out
$17,000 on the bid. wtf
somebody just spent $5K on a bunch of 1s.
what's going on here today?
wow, they're really hiding the buy orders.
i'm talking about some huge blocks too.
can't wait to hear what he says
nothing that's not already known about oncolix.
i suggest you give him a call or at least shoot him an email if you have questions you think he might be able to answer.
if people are emailing him asking if there's going to be a reverse split and aren't getting a response, then they're probably getting the exact response they deserve.
The US/China Innovation and Investment Summit is just around the corner.
https://www.b2match.eu/ucis2017
This could really be an event to watch with dozens of deep pocketed Chinese investors coming in for this.
agree, they aren't buying back shares. i just thought it was interesting the share count had adjusted but it's probably just an adjustment dating back to prior events.
yes.
The company is very responsive.
either this was just some kind of correction or the company has started reducing shares outstanding. makes me wonder about bmak showing up last week.
could be another sign the reverse split won't happen.
Updated May 1
Authorized Shares 500,000,000 a/o May 01, 2017
Outstanding Shares 93,231,633 a/o May 01, 2017
last update was April 4.
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
700,000 fewer outstanding shares listed today than last month.
agreed, except i think a $50M MC could end up being vastly too low, even in the medium term.
don't forget millions in private funding, including a recent investment of probably about $2M from a former CEO of Glaxo!
AEPP
looks like an incredible opportunity!
this is another piece that's being overlooked.
oncolix isn't putting up some shot in the dark here. everybody involved, from the inventor through the CEO all have experience getting drugs successfully through trials.
the amount of information we've learned about oncolix in recent weeks is amazing. the more we learn, the greater the potential seems to be.
i agree. i like using AVXL as a good comp here. they were similar stage in their drug development (had almost twice as many shares OS as AEPP), and pushed solidly from $.15 or so way up into dollars BEFORE a small reverse split to tidy things up. their drug candidate at the time was being mentioned to have billion dollar potential, just like prolanta.
it's also worth noting that price continued to rise and rise after mention and application of the reverse split.
AEPP could actually go well beyond a dollar is all shakes out right. good results, good funding keeps coming in, and of course the CEO understand how to take the price forward. it's all very possible here.
yeah...i'm not sure how we value this, but we do know private investment money is flowing in.
the potential here should be starting to become clear.
well, they have at least few million in assets in their drug portfolio. prolanta likely worth significantly more, but we'll see.
imo, the biggest hurdle they face is the share price, but as i pointed out earlier, all they really need to do is at least triple the current MC and hold the price at $2.00. in whatever form it ends up taking, they shouldn't have any trouble at all getting here provided they release good phase I results as expected.
Oncolix can uplist one year from the day the merger completes.
It's not unlikely they'll be on NASDAQ by the end of 2018 at which point the common shareholder value will have had to more than tripled from current points. That's the bare minimum.
I'd say it's safe to say that Prolanta is worth well north of a few million dollars. The ex-Glaxo CEO who just threw millions in might agree.
http://nasdaq.cchwallstreet.com/NASDAQTools/PlatformViewer.asp?selectednode=chp_1_1_4_3_7_2&manual=%2Fnasdaq%2Fmain%2Fnasdaq-equityrules%2F
Oncolix will need to
1. Complete the reverse merger
2. Wait a year
In that time they'll need to complete all of the appropriate paper work and maintain a closing price of $2.00 for a few months.
Additionally:
(A) Market Value of Listed Securities of at least $50 million (current publicly traded Companies must meet this requirement and the price requirement for 90 consecutive trading days prior to applying for listing if qualifying to list only under the Market Value of Listed Securities Standard);
(B) Stockholders' equity of at least $4 million; and
(C) Market Value of Publicly Held Shares of at least $15 million.
- currently it's under $5 million...
This is simply not correct.
AEPP can uplist to the NASDAQ capital market tier without any revenues.
https://listingcenter.nasdaq.com/assets/initialguide.pdf
I refer anybody interested to page 9.
Market Value of Listed Securities Standard*.
More specifically, 5505(b)(2), which states
great point about the investors knowing more than any of us.
it's also interesting that the a former glaxo ceo just threw in probably over $1 million into oncolix recently.
i don't think these requirements are right.
firstly, i see no evidence that revenues are required to uplist.
AEPP will need to
1. complete the reverse merger
2. wait one year
3. keep the share price above 4
4. keep filings up to date
there are a few other things, but with reverse mergers into shell companies, there can be a different set of standards applied.
https://www.sec.gov/news/press/2011/2011-235.htm
please correct me if i'm wrong...
but the way i see this happening is that NASDAQ is still probably coming to Oncolix no sooner than the fall of 2018. with that said, the company will have plenty of incentive to try to get this stock price to hold over $4 for a month. they will look to significantly grow the price over the next year to get going. it still looks to me like there are enormous gains to be made here...
phase I is to test dosing and toxicity.
this stuff must not only be safe but also be working if the former glaxo ceo just invested. i'm sure they're looking at the results and can see what's ahead. they must know that not only is prolanta safe, but it's working. remember, we know of at least three patients who have fully completed the trial now.
that could be a long time from now, if ever.
there are examples of other companies like Anavex (AVXL) who was in a similar stage as Oncolix with an early stage drug candidate that had multi-billion dollar potential. that company had a huge promotional push to get its message out and went from $.15 to over $7 or something before effectuating their reverse split %25 share reduction to get to NASDAQ.
the price actually continued to rise over time after the reverse split. this company actually had almost twice as many outstanding shares at the time of the reverse split as oncolix has now, btw.
that stock is holding steady at a nice price on NASDAQ at the moment.
the point here is that now we see oncolix starting a PR push with all that's happened in the last two weeks, that a reverse split at this time would be extremely counter productive and would effectively mean the share value they're working to build now would go down the toilet. that really makes no sense to me to do at this time.
much more likely at this time, IMO, is we'll see oncolix continue to push the share price up as the AEPP name changes. they appear to be supremely confident in their product...and investors seem to be agreeing with them. so with that in mind, they know where this can go and it seems highly doubtful they'll give away their company at rock bottom prices with so much to come.
Recapping the last week in Oncolix News:
Oncolix released this interview:
interesting day on tap here